Ignacio Eltit

Urólogo Hospital Felix Bulnes / Fellow endourología y cirugía robótica Clínica Alemana Santiago

[Ignacio Eltit @Eltit_i]

📢 Highlights: Multimorbidity (2 o more chronic conditions) is associate with worse hospital outcomes in Genitourinary cancer patients.

🇨🇱 Retrospective population-based study analyzed 4,028,597 events, involving 18,792 patients with GUC (2019-2021).

https://t.co/b2Lq1Tq0X3

[Sociedad Chilena de Urología @Urolchi]

Estudio publicado en #RevistaSCHU respaldó el uso seguro y eficaz de la prostatectomía laparoscópica asistida por robot (RALP) en pacientes mayores de 75 años con cáncer de próstata localizado https://t.co/VPOqOK5mLU

[Adam B. Weiner, MD @Adam_Weiner535]

🚨 PRIMARY2: PSMA-PET moves into the prostate cancer diagnostic pathway

📰Just out in @TheLancetOncol

🧬 660 biopsy-naïve pts w/ suspected significant PCa + PI-RADS 3 MRI or PI-RADS 2 MRI w/ high-risk clinical features

⚖️Randomized to [⁶⁸Ga]Ga-PSMA-11 PET-CT vs systematic transperineal biopsy.

🧭 PRIMARY score 1–2 → surveillance. PRIMARY score 3–5 → PSMA-targeted biopsy.

🎯 PSMA-PET triage was non-inferior for clinically significant PCa detection: 12% vs 16%

✂️ Nearly half avoided biopsy: 49% (163/331).

📉 Clinically insignificant cancer detection dropped substantially: 14% vs 32%.

⚖️ Big implication: fewer biopsies + less overdiagnosis, without losing significant cancers.

💡Caveat: follow-up ongoing; health economics + validation w/ other PSMA tracers needed

🔗https://t.co/REt8Wm15G1

@PCFnews @PCF_Science @renalandurology @UrologyTimes @urotoday

[Jose Antonio Salvadó @DRSALVADOSTONE]

Proud to share our latest work in World Journal of Urology @FullaJuan @bsc_urology

First-in-human experience using Asurys™, an automated intrarenal pressure control system integrated into flexible ureteroscopy.
A new step toward safer, pressure-guided endouro

[Mario I Fernandez @marigfern]

Sigue BCG siendo el estándar en cancer de vejiga no músculo invasor de alto riesgo? Interesante debate en Webinar @CAU_URO este Sábado👇🏻con excelentes ponentes @DrFelixGuerrero y Miguel Gonzalez
@ResidentesCAU @RodriguezFaba @joanfundi @GustavoVillold4 @HegeltS
@Nolazco_JI

[Confederación Americana de Urología (CAU) @CAU_URO]

💡 Ayúdanos a estudiar con esta encuesta sobre el tratamiento del cáncer de vejiga no músculo invasivo. Los datos recolectados serán utilizados únicamente con fines de investigación y no para usos comerciales🫡
Link👉🏼 https://t.co/kLKSyhLyJn

@siupurol

[Michael Hofman @DrMHofman]

... how common is PSMA-negative significant prostate
cancer? In the proPSMA study it was 3.3%

Hot of the press in @JournalofNucMed: https://t.co/S6phT0F03X

Wonderful work from @davcmed and team @pros_tic including @ButeauJames @declangmurphy

[Ignacio Eltit @Eltit_i]

🎯 Implications: Multimorbidity among GUC patients is linked to increased costs, longer hospital stays, higher mortality, and greater hospitalization severity

[Ignacio Eltit @Eltit_i]

📢 Highlights: Multimorbidity (2 o more chronic conditions) is associate with worse hospital outcomes in Genitourinary cancer patients.

🇨🇱 Retrospective population-based study analyzed 4,028,597 events, involving 18,792 patients with GUC (2019-2021).

https://t.co/b2Lq1Tq0X3

[Ignacio Eltit @Eltit_i]

🏥 Hospital mortality was higher in multimorbidity patients (7.5% vs. 3.7%), who also had longer stays (mean 8 vs. 5 days) and higher rates of moderate/major severity hospitalization.

[Juan Gómez Rivas @JGomezRivas]

📢 Study Highlights: PSA Decline as a Predictor in mHSPC Treatment

A retrospective multicenter study analyzed 633 patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide (2018-2023). PSA response at 3 months was strongly linked to outcomes:

✅ Complete Response (PSA ≤0.02 ng/ml): 27% of patients, 92% radiologic progression-free survival (rPFS) at 24 months.
⚠️ Partial Response (PSA >0.02-0.2 ng/ml): 42% of patients, 86% rPFS at 24 months.
❌ Incomplete Response (PSA >0.2 ng/ml): 31% of patients, 63% rPFS at 24 months, with nearly 50% progressing within 2 years.

🔑 Predictive factors for a complete PSA response:
•Use of next-generation imaging.
•PSA <50 ng/ml at diagnosis.

💡 Implications: Early PSA response after 3 months of treatment provides a powerful prognostic tool to guide therapy for mHSPC. Heterogeneity among patients and data quality remain key limitations

https://t.co/sbBVvBNwAK

[Sociedad Chilena de Urología @Urolchi]

#CongresoSCHU2024 Estos son los ganadores de los Trabajos Libres:
Póster: Dr. Alfredo Aliaga
Videos:
1: Dra. Melissa Cifuentes
2: Dr. Joaquín Gurovich
3: Dr. Orlando Mejías
Ciencias Básicas:
Dra. Melissa Cifuentes
Presentación oral:
1: Dr. Alejandro Rojas
2 y3: Dr. Ignacio Eltit

[José Ignacio Acuña @JIgnacioAcuna]

Es muy satisfactorio ver, a los residentes que entran a programas de formación, con una técnica de #HoLEP ya instalada, avanzar muy rápido en el aprendizaje de esta técnica.

Ayer Dr. Eltit @Eltit_i, R3 en HFBC completó este caso,
https://t.co/TqdVSiEbkk

[Ignacio Eltit @Eltit_i]

@HXtensions Hi we are a Urologic Team in Santiago, Chile. We perform robotic and laparoscopic surgery. We are very interested in yours products. We want to try it and hopefully start a mew partnership. Tell me how we can make this happen.

[Mario I Fernandez @marigfern]

No se lo pierdan!

Mañana Viernes 06/10 en #CAU2023

Como mejorar mis resultados en Cistectomia radical?

Salón 4
7:00 - 8:30 AM

Docentes
@RodriguezFaba 🇪🇸@GustavoVillold4 🇦🇷
@ Miguel Gonzalez Dominguez🇲🇽
@marigfern 🇨🇱

Los esperamos!

@Urolchi @CAU_URO

[Société Internationale d'Urologie Journal @SIU_Journal]

In this issue of #SIUJ, the impact of Public Policies and Type of Insurance on the Burden of Bladder Cancer–Related Inpatient Health Care in Chile. #OpenAccess #Journal #UroSoMe
Read the Research: https://t.co/0haqEjCMg3
Check out the latest issue: https://t.co/Z7vUtallrc

[Mario I Fernandez @marigfern]

Disparidades en desenlaces por cancer de vejiga en Chile segun de previsión (FONASA vs. ISAPRE). Independiente de ello, gran aumento de carga asistencial por esta enfermedad en últimos 20 años
@Urolchi @DrFmarchantUro @dr_enriqueelias @uroledezma @sguzmank @UDD_FM @LuisEbel1